Biofidelity Secures $24M Funding to Expand Cancer Genomic Technology.
Biofidelity, a genomic technology company based in Cambridge, UK and Morrisville, NC, recently secured $24M in funding. The funding round was supported by investors such as Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures. Dr. Barnaby Balmforth, the CEO of Biofidelity, leads the company in its mission to enhance and prolong the lives of cancer patients by enhancing therapy targeting, detecting treatment resistance early, and monitoring treatment response regularly.
The company plans to utilize the funds to expedite its growth initiatives, including expanding commercially and clinically in the United States to promote the adoption of ASPYRE®-Lung.
This innovative test simplifies and speeds up the detection of biomarkers for non-small cell lung cancer (NSCLC), allowing healthcare providers to determine the most suitable treatment for each patient within days rather than weeks and at a reduced cost compared to existing sequencing tests. Furthermore, the investment will facilitate the establishment of a specialized manufacturing facility in the United Kingdom and propel efforts to expand the company's technology platforms.
In response to the funding news, Barnaby Balmforth expressed, “This substantial investment underscores the confidence of our investors in Biofidelity's proprietary technologies and our vision of democratizing precision medicine for all patients.” The company's strategic focus on enhancing cancer care through advanced genomic technologies positions it as an emerging leader in the field, with a clear trajectory for impact and growth in the coming years.
They've invested in Biofidelity
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK